[{"address1": "5750 Explorer Drive", "address2": "Suite 404", "city": "Mississauga", "state": "ON", "zip": "L4W 0A9", "country": "Canada", "phone": "905 602 5840", "website": "https://www.cipherpharma.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Craig J. Mull", "title": "Interim CEO & Chairman of the Board", "fiscalYear": 2023, "totalPay": 85198, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryan  Jacobs", "title": "Chief Financial Officer", "fiscalYear": 2023, "totalPay": 322408, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Emilio  Presti", "title": "Director of Sales & Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hamed  Ghanei", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.94, "open": 12.0, "dayLow": 11.86, "dayHigh": 12.12, "regularMarketPreviousClose": 11.94, "regularMarketOpen": 12.0, "regularMarketDayLow": 11.86, "regularMarketDayHigh": 12.12, "beta": 1.201, "trailingPE": 13.200001, "forwardPE": 23.76, "volume": 950, "regularMarketVolume": 950, "averageVolume": 37642, "averageVolume10days": 9210, "averageDailyVolume10Day": 9210, "bid": 11.87, "ask": 11.91, "bidSize": 40000, "askSize": 40000, "marketCap": 305238784, "fiftyTwoWeekLow": 3.13, "fiftyTwoWeekHigh": 14.6, "priceToSalesTrailing12Months": 13.774935, "fiftyDayAverage": 12.0208, "twoHundredDayAverage": 7.6669, "currency": "USD", "enterpriseValue": 256240032, "profitMargins": 1.0200801, "floatShares": 14493100, "sharesOutstanding": 25588600, "sharesShort": 11427, "sharesShortPriorMonth": 48425, "sharesShortPreviousMonthDate": 1477872000, "dateShortInterest": 1480464000, "sharesPercentSharesOut": 0.0004, "heldPercentInsiders": 0.42001, "heldPercentInstitutions": 0.0137600005, "shortRatio": 0.97, "impliedSharesOutstanding": 25693500, "bookValue": 3.682, "priceToBook": 3.2265074, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": -0.025, "netIncomeToCommon": 22604000, "trailingEps": 0.9, "forwardEps": 0.5, "enterpriseToRevenue": 11.564, "enterpriseToEbitda": 21.229, "52WeekChange": 2.7714286, "SandP52WeekChange": 0.39389753, "exchange": "OQX", "quoteType": "EQUITY", "symbol": "CPHRF", "underlyingSymbol": "CPHRF", "shortName": "Cipher Pharmaceuticals, Inc.", "longName": "Cipher Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1138890600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "33ee6a68-9bd5-3305-98c7-75445d99f34d", "messageBoardId": "finmb_8201659", "gmtOffSetMilliseconds": -14400000, "currentPrice": 11.88, "recommendationKey": "none", "totalCash": 47984000, "totalCashPerShare": 1.875, "ebitda": 12070000, "totalDebt": 296000, "quickRatio": 10.533, "currentRatio": 11.184, "totalRevenue": 22159000, "debtToEquity": 0.333, "revenuePerShare": 0.908, "returnOnAssets": 0.07904, "returnOnEquity": 0.28433, "freeCashflow": 5532500, "operatingCashflow": 17047000, "revenueGrowth": 0.003, "grossMargins": 0.81082, "ebitdaMargins": 0.5447, "operatingMargins": 0.48812, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-28"}]